key: cord-1040261-is74kf31 authors: Corral, Juan E.; Hoogenboom, Sanne A.; Kröner, Paul T.; Vazquez-Roque, Maria I.; Picco, Michael F.; Farraye, Francis A.; Wallace, Michael B. title: COVID-19 polymerase chain reaction testing before endoscopy: an economic analysis date: 2020-04-28 journal: Gastrointest Endosc DOI: 10.1016/j.gie.2020.04.049 sha: e6dc956bbbe0f57a6e3b6de69f7df9a9352971ab doc_id: 1040261 cord_uid: is74kf31 Abstract Background and Aims The COVID-19 pandemic has limited endoscopy utilization, causing significant health and economic losses. We aim to model the impact of PCR testing into resuming endoscopy practice. Methods We performed a retrospective review of endoscopy utilization during the COVID-19 pandemic for a baseline reference. A computer model compared 3 approaches―Strategy 1: endoscopy for urgent indications only; Strategy 2: testing for semi-urgent indications; and Strategy 3: testing all patients. Analysis was made under current COVID-19 prevalence, and projected prevalence of 5% and 10%. Primary outcomes were number of procedures performed/cancelled. Secondary outcomes were direct costs, reimbursement, personal protective equipment used and personnel infected. Disease prevalence, testing accuracy, and costs were obtained from literature. Results During the COVID-19 pandemic, endoscopy volume was 12.7% of expected. Strategy 2 and 3 were safe and effective interventions to resume endoscopy in semi-urgent and elective cases. Investing 22USD and 105USD in testing per patient allowed completing 19.4% and 95.3% of baseline endoscopies respectively. False negative results were seen after testing 4,700 patients (or 3 months applying Strategy 2 in our practice). Implementing PCR testing over 1 week in United States would require 13 and 64 million USD, with a return of 165 and 767 million USD to providers, leaving 65 and 325 health care workers infected. Conclusion PCR testing is an effective strategy to restart endoscopic practice in United States. PCR screening should be implemented during the second phase of the pandemic, once the healthcare system is able to test and isolate all suspected COVID-19 cases. The first case of 2019 novel coronavirus in United States was confirmed on January 20, 2020. 1 The first case at our institution was confirmed on March 14, 2020. During the initial weeks of the COVID-19 pandemic, laboratory testing for the SARS-CoV-2 virus was provided by the Florida Department of Health only, and turnaround result time ranged between 4 and 10 days. Parallel to the exponential number of patients requiring hospitalization for COVID-19, most hospitals, clinics, and endoscopy centers across the world started limiting endoscopy services to emergent and urgent procedures only. A recent survey shows that there is no consensus among gastroenterologists regarding the best timing to perform semi-urgent procedures for non-life-threatening conditions amid the COVID-19 pandemic. 2 Deferring semi-urgent procedures may lead to delay in the diagnosis of critical conditions (eg, localized pancreatic cancer), closing a narrow window of opportunity for endoscopic treatment (eg, ablation of Barrett's esophagus with dysplasia and resection of advanced colon adenomas) and has already led to substantial economic losses. On March 24, 2020, our institution's laboratory started performing real-time polymerase chain reaction (PCR) testing for SARS-CoV-2 virus, with results being available within 3 to 4 hours. This was possible using a combination of commercially acquired and in-house developed reagents, and working with providers early in the COVID-19 outbreak. The following day all hospitalized patients were tested. Five days later a policy to test all patients within 48 hours before having an outpatient endoscopic or surgical procedure was implemented. The primary objective of this study was to use a decision tree analysis to compare different approaches for COVID-19 testing in patients requiring semi-urgent and elective endoscopy. We first modeled the impact of this policy at our institution and then extrapolated to all cases performed in the United States. The secondary objective was to identify clinical determining factors under which different strategies are more effective and safer to resume outpatient endoscopy work-flow. A retrospective review of endoscopic procedures performed at our institution was conducted over a one-week period (ie, March 4, 2019 -March 10, 2019). This represents our baseline practice outside of the COVID-19 pandemic period. We recorded patient demographics, procedure type and indication of all procedures scheduled during that time. Procedure indication was grouped into 3 categories: emergent/urgent (procedure that should be performed within 24 hours), semi-urgent (procedures that should be performed between 24 hours and 7 weeks), and elective (procedures that could be performed within 8 or more weeks). The classification of procedures was adapted from a survey of gastroenterologists who had to cancel procedures during the COVID-19 pandemic (Supplement , Table S1 ). 2 During the week of March 23, 2020 to March 29, 2020, our institution started a policy to cancel all semi-urgent and elective procedures. On March 24, PCR testing for SARS-CoV-2 virus became available in-house, and testing was performed systematically. We performed a second review of procedures performed between March 30, 2020 and April 5, 2020. During this week all patients were tested within 48 hours before their planned endoscopic procedure. This represents our baseline practice during the COVID-19 pandemic period. (Table 1) The assay used at our institution is the Cobas SARS-CoV-2 test (Roche Molecular Systems, Inc, Basel, Switzerland). It is a TaqMan probe-based, real-time, reverse transcription-PCR assay designed for qualitative detection of SARS-CoV-2 RNA from human nasopharyngeal and oropharyngeal swabs. 3 It is considered an in vitro diagnostic test that received FDA emergency use authorization. 3, 4 Performance reported by the manufacturer and by 2 research groups constituted our best scenario. 5,6 A third research group evaluated a similar PCR assay and comparatively investigated the diagnostic value and consistency of CT imaging in patients with COVID-19. 7 The diagnostic accuracy reported in vivo by this group was lower and constituted our worse scenario (Table 2) . A decision tree model was created comparing 3 potential strategies using PCR COVID-19 testing to triage and perform endoscopic procedures at our hospital. The strategies compared in Figure 1 are: • Strategy 1: Patients requiring an emergent/urgent endoscopy (within 24 hours) are tested. Endoscopy is performed regardless of result. High-risk personal protective equipment (PPE) and decontamination after procedure is used for each emergent/urgent endoscopy. 8 All other procedures (semi-urgent and elective) are postponed. • Strategy 2: Patients requiring emergent/urgent and semi-urgent procedures are tested within 48 hours before the planned endoscopic procedure. All emergent/urgent cases are completed regardless of PCR result using high-risk PPE. Semi-urgent cases with a negative result proceed to endoscopy using low-risk PPE. Semi-urgent cases with a positive result are postponed. All elective procedures are postponed. • Strategy 3: PCR test is performed on all patients within 48 hours. All emergent/urgent cases are completed regardless of PCR result using high-risk PPE. Semi-urgent and elective cases with a negative result proceed to endoscopy using low-risk PPE. Semi-urgent and elective cases with a positive result are postponed. Our economic model focused on short-term outcomes over 7 days. We did not measure the added benefit of identifying an asymptomatic patient with COVID-19 who presented for an elective procedure. We did not measure the impact of respiratory failure developed during endoscopy, the need to perform endotracheal intubation during endoscopy or mortality associated to COVID-19. Our analysis did not include the risk of patients contracting COVID-19 from their visit to our endoscopy center. The primary outcomes were the added cost of PCR testing per patient and the total number of procedures performed using each strategy. Secondary outcomes were the number of patients with COVID-19 that underwent endoscopy without high-risk PPE (for a false negative result), healthcare staff infected, number of healthy patients who had their procedure postponed (for a false positive result), and economic revenue for the endoscopy center. The analysis was completed under 3 disease scenarios (with prevalence at the moment of writing, 5% and 10%). We estimated that performing an endoscopic procedure on a false positive case under urgent circumstances would translate into wasting high-risk PPE in four staff members (ie, physician, nurse, anesthetist and technician). Cases with semi-urgent and elective indications and a positive test result would be postponed. On the other end, a case with a false negative test result would undergo endoscopy with the use of low-risk PPE. 8 When current estimates that SARS-CoV-2 virus has an infective rate (R 0 ) of 1.5 to 3.5 in the community are used, performing such endoscopic procedures could infect a similar number of healthcare workers. 9 Clinical probabilities and other inputs We assumed that the probability of transmitting COVID-19 was independent of the endoscopic procedure requested. Clinical probabilities were obtained from different sources ( Table 2 ). The presumed prevalence of COVID-19 was calculated from reports from Duval County, Florida on April 2, 2020. We used a reverse calculation using a corrected infection fatality rate (cIFR) of 1.3% (95% CI, 0.38-3.6) (Supplementary Table 2 ). 10 Primary analysis was performed using cost estimates from the Center for Medicare Services data for hospital outpatient department payments in 2020. [11] [12] [13] Because Medicare payments vary geographically, depending on local operating costs; we varied our baseline costs by using a sensitivity analysis through the ranges shown in Table 2 . Ranges were derived by adding 25% or subtracting 25% from the baseline estimate. Secondary analysis was performed using costs for ambulatory surgery centers in 2020 (Supplementary Table 3 ). The cost of PPE was separated into low-risk and high-risk, which was calculated based on the recommendations by the Milan endoscopy group (Supplementary Table 4 ). 8 Compared with the Milan recommendations, the American Gastroenterological Association (AGA) Institute advocates for high-risk PPE (ie, N95 masks and double gloves) for all upper and lower GI procedures. 14 We selected the former because AGA recommendations were written assuming absence of widespread reliable rapid testing for the diagnosis of COVID-19. Only direct costs for a third-party payer perspective were considered, which were adjusted to the 2020 U.S. dollar. We did not perform any adjustments for inflation or discounting. Additional details of cost calculations are provided in the supplement section. The robustness of the model was tested by performing probabilistic sensitivity analysis modifying the important clinical probabilities and cost estimates. Clinical probabilities followed a beta distribution and costs ranges followed a normal distribution. We performed a second-order Monte Carlo simulation with 1,000 computer iterations of our model. 15 By using tracker variables, the number of endoscopies performed was compared among the 3 strategies. Sensitivity analysis was done with Bayes revision. • Threshold analysis was performed to determine clinical limits under which all cases are performed with adequate PPE (ie, no false negative cases). • Tornado diagrams were created to compare the weight of different variables (PCR testing performance, costs of anesthesia and endoscopic procedures, etc) into the final estimates of our model. Using published reports, we estimated the number of needed colonoscopies, esophagogastroduodenoscopies (EGD), flexible sigmoidoscopies (FlexSig), endoscopic retrograde cholangiopancreatography (ERCP) and EUS in United States for 1 week in 2020, assuming COVID-19 had not developed. [16] [17] [18] We projected the effects of the 3 strategies in resuming endoscopic procedures toward that goal (Supplementary Table 5 ). Patients presenting early in our model may recover from COVID-19 and could be considered for endoscopy few days later. The World Health Organization recommends at least 14 days of quarantine, and the U.S. Center of Disease Control and Prevention at least 3 days after fever resolution. 19, 20 For simplicity of the analysis, these patients were deemed poor endoscopy candidates throughout the rest of the study period. Given the relatively short period of time analyzed, we did not perform half-cycle corrections. When estimates were unavailable or significant discrepancies were found in published literature, 3 authors (S.A.H., P.T.K., and M.B.W.) would discuss and agree on a final estimate. The decision tree was generated and analyzed using decision analysis software (TreeAge Pro; Williamstown, Mass, USA). Our study protocol was approved by Mayo Clinic IRB (protocol 20-003245). During the COVID-19 pandemic, the weekly endoscopy volume at our institution decreased to 12.7% of baseline. The main difference was seen in elective procedures: only 2 elective cases were performed during the week corresponding to the COVID-19 pandemic compared with 296 during that week in 2019. pandemic showed that PCR testing is a safe and effective intervention to resume endoscopy in semi-urgent and elective cases. Our analysis showed that testing under strategy 3 allows completing more endoscopies than the other 2 strategies (Table 2 ). Implementing strategy 2 and 3 translates into expending 22 and 105 U.S. Dollars (USD), respectively, in PCR testing per patient but allows an increase to 19.4% and 95.3% of baseline endoscopies. At the current disease prevalence (122 cases per 100,000 individuals), implementing all 3 strategies over 1 week is unlikely to diagnose a true positive case (Table 3) and false negatives would also be exceedingly rare given low population prevalence, even with moderate test sensitivity. In our initial model all patients scheduled for a semi-urgent or elective procedure who tested positive for COVID-19 would be rescheduled. Our results were consistent over 1,000 reiterations of the Monte Carlo simulation ( Figure 2 ). False negative results were only seen after testing 4,700 patients, or 3 months using Strategy 2 in our practice (assuming disease prevalence remains stable). If disease prevalence increased to 5%, there was one false negative result every week under strategy 2 and one false negative result every 3 days under strategy 3. This translates into 1 to 10 infected health care workers over a 1-week period (Table 3) . Sensitivity analyses showed that the economic revenue for the hospital is greatly impacted by the cost of colonoscopies, EGD, extras (eg, laboratories, pathology and imaging) and ERCP. The revenue for the hospital is much less impacted by the test performance (ie, true positive, true negative, false positive and false negative values) (Supplementary Fig. 1 ). Implementing nationwide PCR testing using strategies 1, 2, and 3 would require investing 6, 13, and 64 million USD weekly under each strategy. This would yield a return of 75, 165, and 767 million USD to providers. Assuming these patients are scoped with low-risk PPE and R 0 rate is 1.5-3.5 would leave 26, 65 and 325 healthcare workers infected for each strategy, respectively. Testing patients for SARS-CoV-2 virus with PCR before endoscopy is an effective preventive strategy to resume endoscopy practice in different clinical scenarios. At the present rate of infection in low-prevalence populations, such as our center, this intervention seems safe over a 3-month period. Despite the potential gains of PCR testing in all patients requiring endoscopy during the COVID-19 epidemic, we cannot overemphasize the importance of following adequate PPE use protocols. We recommend reviewing "Coronavirus (COVID-19) outbreak: What the endoscopy department should know" and review the dynamic society recommendations periodically. 8, 14 The biggest determining factor in the safety and effectiveness of this intervention is by far the disease prevalence. should be offered as an alternative to average-risk individuals seeking colorectal cancer screening. Our 3 prevalence scenarios evaluate a sizeable spectrum of the COVID-19 pandemic. Even though some computer models suggest that the prevalence of COVID-19 may reach an excess of 214 million Americans (65% of the total population), this represents cumulative prevalence counting patients that have been exposed and recovered. 21 Considering the clinical duration of COVID-19 is usually 2 to 3 weeks, our point estimates are well-above maximum incidences reported in New York, Spain and Italy at the moment of writing (460, 187 and 171 per 100,000 residents, respectively). Without widespread testing the population, the best estimates of disease prevalence are calculated retrospectively based on mortality rates. Such estimates lag days or weeks from actual prevalence. With current social distancing strategies, we expect new cases continue to appear although at a lesser rate, potentially matching recovery rates. We speculate that the transmission rate in the endoscopy unit is similar to that in the community. Most calculations of R 0 originate from experience in China in a community setting. 9 The transmission rate within the endoscopy unit remains unknown. and the R 0 range used (1.5-3.5) is likely an overestimate. Case reports show that appropriate use of PPE (either with surgical masks or N95 masks), hand hygiene and other standard procedures can reduce transmission rate up to zero (0/41 healthcare workers exposed in Singapore). 9, 25 On the other end, non-clinical personnel (eg, front desk, transportation) will be infected if they do not follow same procedures. The quality of any decision tree analysis depends on the quality of probabilities and other the input data to the computer model. A number of external factors affect diagnostic performance including sampling operations, specimen source (oral, nasal swab), sampling timing (asymptomatic, symptomatic, recovery phase), and detection kit selected. 22 We consider our estimates on PCR accuracy to be conservative and lower than that reported by manufacturer in vitro. The test manufacturer reports a level of detection close to ~100-200 copies/ml of sample. 3 For reference, a cohort of 23 symptomatic patients in Hong Kong had a median viral load of ~150,000 copies/mL on the day of hospitalization. 23 Current estimates on PCR testing sensitivity and specificity of the SARS-CoV-2 assays are based on analytical validations. These measurements reflect performance against contrived samples (ie, spiked samples) and control material. There are no estimates of "clinical sensitivity" in patients with symptomatic COVID-19 and subclinical SARS-CoV-2 infection. The Wuhan study did not evaluate the cause for pulmonary infiltrates in those patients with negative PCR and positive CT findings (ie, infection with another virus or bacteria, inappropriate timing, testing misuse or malfunction). 7 For this reasons we allowed a broad confidence interval for sensitivity and specificity. These estimates should be measured in a prospective fashion with patients at different ends of the clinical spectrum (both timing and disease severity). We are conducting a prospective analysis of cases tested in our institution for that purpose. Of all potential outcomes of the test, false negative results are the most relevant for isolation and personal protection. Exposing a healthcare worker to SARS-CoV-2 because of PCR testing limitations has significant ethical implications. The most common reported cause for a false negative is low viral load. 5, 6 It is conceivable that a false negative patient has a lower viral load and likely is less contagious (lower R 0 factor). These strategies should be avoided at institutions or geographic areas where the prevalence of active cases approaches 5%. We assumed that the hospital or endoscopy center would be responsible for the costs of SARS-CoV-2 PCR test. In United States, Medicare services and most insurance programs reimburse the cost of COVID 19 testing (paying between 36-51 USD per test). These reimbursements programs will favor more comprehensive testing strategies. On the other end of the spectrum, false positive results can lead to potential waste of valuable PPE, as well as waste of other resources used in disinfection and isolation. Postponing a semi-urgent or elective case for a false positive test result would be preferred. Alternatively, performing a second PCR or antibody testing (IgG serum) would be potential options. The most critical estimates were PCR test performance and procedure classification. We were cautious to allow a broad range of sensitivity and specificity for the PCR test performance including worst case scenarios. Additionally, we performed a systematic retrospective review of cases performed in March 2019 and 2020. Our analysis accounts for clinical uncertainties and valid statistical measures with a second-order Monte Carlo simulation. One of the limitations was the inability to include the effect of respiratory symptoms and patients with active disease into our model. We presumed that symptomatic patients may proceed straight to a general provider and miss their scheduled endoscopy. Both patient and providers may contract COVID-19 from other health care workers in the endoscopy lab. We did not accounted for periodic screening of healthcare workers and this population represents 10% to 20% of all positive cases. 24 Our study did not evaluate emerging tests for serological exposure (IgM/IgG) and the potential that these patients may be immunized to future infections. As data emerges on the accuracy of these tests, a strategy combining rapid viral PCR and serology should be studied. Despite the sensitivity analysis and Monte Carlo simulation, our model represents a simplification of a complex and dynamic process. We agree that the definition of endoscopy candidate is a broad umbrella term that covers The American Enterprise Institute has proposed a road map to reopen regular services as COVID-19 transmission is brought under control. 26 They describe a transition through four different phases (Table 5) . We consider this intervention to be ideally implemented in Phase 2: once each center is able to safely diagnose, treat and isolate COVID-19 cases and their contacts. The value of PCR testing grows as the prevalence of COVID-19 increases, with an inversion of the false positive:true positive ratio (with the caveats of false negatives discussed above). Upscaling this intervention across the country will increase healthcare workers exposure to SARS-CoV-2 virus. By our estimates, this means that 325 or more healthcare workers across the country will potentially become infected in the endoscopy unit on a weekly basis. Although constituting a fundamental aspect of the strategy, testing alone is not sufficient enough to reopen practice. Testing should be integrated into an institution-wide plan that coordinates the notification of results before returning to the institution, ensures isolation and promotes follow-up monitoring. Additional strategies that can be implemented from the endoscopy unit are suggested in Table 5 . Finally, our findings are applicable to ambulatory surgery centers and other facilities like dialysis or infusion centers. Further computer models should estimate the infection risk in such institutions and potential gains of PCR testing with different patient populations (eg, chronically immunosuppressed). Our model was designed for healthcare institutions in high-and upper-middle-income countries, but is likely prohibitive in countries with limited testing and other resources. In such instances, symptomatic patients, patients with exposure to confirmed cases and healthcare workers remain the priority in testing. This economic analysis shows that PCR testing is an effective strategy to restart endoscopic practice in the United States. Our findings support Strategy 3, which involves testing all patients, performing urgent endoscopy irrespective of testing result, as well as endoscopy in the rest of SARS-CoV-2 negative cases, but the extent of testing will rely on local resources and disease prevalence. The implementation of PCR screening is ideal for the second phase of the COVID-19 pandemic, once the health system is able to test and isolate all suspected COVID-19 cases and critical care capacity is secured. Further research is needed to measure PCR performance in vivo over different clinical scenarios while, in parallel, we continue to develop effective medical treatments. a. Combined cases were recorded as the one with highest reimbursement (eg, Colonoscopy + EGD = colonoscopy, EUS + EGD = EUS) b. COVID-19 testing was implemented this week. First COVID-19 guidelines were circulated across our institution in 2/28/2020. Authors' calculation. Real time PCR using cobas SARS-CoV-2 test. 3 Reported sensitivity of 95% when there were at least 689.3 copies/mL. 6 In a small cohort of symptomatic admitted patients viral load at admission was ~150.000 copies/mL. 23 a. Adding testing, personal protective equipment (low and high risk) and room decontamination (Details in Supplement). b. Adding Medicare payments for procedure, anesthesia and extras (management, laboratories, EKG, imaging, pathology, etc) (Details in Supplement). $13 Abbreviations: EGD: Esophagogastroduodenoscopy, Colon: Colonoscopy, FlexSig: Flexible sigmoidoscopy, ERCP: Endoscopic retrograde cholagiopancreatography, EUS: Endoscopic ultrasound. a. Calculations in Supplement Table S5 First Case of 2019 Novel Coronavirus in the United States What Constitutes Urgent Endoscopy? A Social Media Snapshot of Gastroenterologists' Views During the COVID-19 Pandemic COVID-19), cobas® SARS-CoV-2 -Molecular Systems Detection of 2019 novel coronavirus (2019-nCoV) by realtime RT-PCR Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases COVID-19) outbreak: what the department of endoscopy should know Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship Colonoscopy-related Costs, Medicare Fee-for-Service Beneficiaries who Received a Screening or Diagnostic Colonoscopy AGA Institute Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity Burden of gastrointestinal disease in the United States: 2012 update millioncolonoscopies-are-performed-annually-in-the-united-states/.) 19. Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-19). Interim guidance html.) 21. Worst-Case Estimates for U.S. Coronavirus Deaths. The New York Times Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Annals of Internal Medicine 2020. 26. National coronavirus response: A road map to reopening Novel Coronavirus Response (COVID-19). Florida Department of Health Estimates of the severity of coronavirus disease 2019: a model-based analysis Authors would like to thank Matthew J. Binnicker PhD for technical assistance in reviewing our diagnostic accuracy estimates.